Hiroki Osumi (Junko Fujisaki)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 25

Top Topics

Top Venues

Journal of cancer research and clinical oncology

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Hiroki Osumi, Eiji Shinozaki, Yoshiaki Nakamura, Taito Esaki, Hisateru Yasui, Hiroya Taniguchi, Hironaga Satake, Yu Sunakawa, Yoshito Komatsu, Yoshinori Kagawa, Tadamichi Denda, Manabu Shiozawa, Taroh Satoh, Tomohiro Nishina, Masahiro Goto, Naoki Takahashi, Takeshi Kato, Hideaki Bando, Kensei Yamaguchi, Takayuki Yoshino
Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudy. Nature communications 15 (1) (2024)
Hiroki Osumi, Eiji Shinozaki, Yoshiaki Nakamura, Taito Esaki, Hisateru Yasui, Hiroya Taniguchi, Hironaga Satake, Yu Sunakawa, Yoshito Komatsu, Yoshinori Kagawa, Tadamichi Denda, Manabu Shiozawa, Taroh Satoh, Tomohiro Nishina, Masahiro Goto, Naoki Takahashi, Takeshi Kato, Hideaki Bando, Kensei Yamaguchi, Takayuki Yoshino
Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudy. Nature communications 15 (1) (2024)
Koshiro Fukuda, Hiroki Osumi, Yuri Yoshinami, Akira Ooki, Atsuo Takashima, Takeru Wakatsuki, Hidekazu Hirano, Izuma Nakayama, Kota Ouchi, Ryoichi Sawada, Shota Fukuoka, Mariko Ogura, Daisuke Takahari, Keisho Chin, Hirokazu Shoji, Natsuko Okita, Ken Kato, Naoki Ishizuka, Narikazu Boku, Kensei Yamaguchi, Eiji Shinozaki
Efficacy of anti-epidermal growth factor antibody rechallenge in RAS/BRAF wild-type metastatic colorectal cancer: a multi-institutional observational study. Journal of cancer research and clinical oncology 150 (7) (2024)
Koshiro Fukuda, Hiroki Osumi, Yuri Yoshinami, Akira Ooki, Atsuo Takashima, Takeru Wakatsuki, Hidekazu Hirano, Izuma Nakayama, Kota Ouchi, Ryoichi Sawada, Shota Fukuoka, Mariko Ogura, Daisuke Takahari, Keisho Chin, Hirokazu Shoji, Natsuko Okita, Ken Kato, Naoki Ishizuka, Narikazu Boku, Kensei Yamaguchi, Eiji Shinozaki
Efficacy of anti-epidermal growth factor antibody rechallenge in RAS/BRAF wild-type metastatic colorectal cancer: a multi-institutional observational study. Journal of cancer research and clinical oncology 150 (7) (2024)
Koshiro Fukuda, Hiroki Osumi, Yuri Yoshinami, Akira Ooki, Atsuo Takashima, Takeru Wakatsuki, Hidekazu Hirano, Izuma Nakayama, Kota Ouchi, Ryoichi Sawada, Shota Fukuoka, Mariko Ogura, Daisuke Takahari, Keisho Chin, Hirokazu Shoji, Natsuko Okita, Ken Kato, Naoki Ishizuka, Narikazu Boku, Kensei Yamaguchi, Eiji Shinozaki
Efficacy of anti-epidermal growth factor antibody rechallenge in RAS/BRAF wild-type metastatic colorectal cancer: a multi-institutional observational study. Journal of cancer research and clinical oncology 150 (7) (2024)
Hiroki Osumi, Eiji Shinozaki, Yoshiaki Nakamura, Taito Esaki, Hisateru Yasui, Hiroya Taniguchi, Hironaga Satake, Yu Sunakawa, Yoshito Komatsu, Yoshinori Kagawa, Tadamichi Denda, Manabu Shiozawa, Taroh Satoh, Tomohiro Nishina, Masahiro Goto, Naoki Takahashi, Takeshi Kato, Hideaki Bando, Kensei Yamaguchi, Takayuki Yoshino
Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudy. Nature communications 15 (1) (2024)
Koshiro Fukuda, Hiroki Osumi, Yuri Yoshinami, Akira Ooki, Atsuo Takashima, Takeru Wakatsuki, Hidekazu Hirano, Izuma Nakayama, Kota Ouchi, Ryoichi Sawada, Shota Fukuoka, Mariko Ogura, Daisuke Takahari, Keisho Chin, Hirokazu Shoji, Natsuko Okita, Ken Kato, Naoki Ishizuka, Narikazu Boku, Kensei Yamaguchi, Eiji Shinozaki
Efficacy of anti-epidermal growth factor antibody rechallenge in RAS/BRAF wild-type metastatic colorectal cancer: a multi-institutional observational study. Journal of cancer research and clinical oncology 150 (7) (2024)
Shohei Udagawa, Akira Ooki, Eiji Shinozaki, Koshiro Fukuda, Kensei Yamaguchi, Hiroki Osumi
Circulating Tumor DNA: The Dawn of a New Era in the Optimization of Chemotherapeutic Strategies for Metastatic Colo-Rectal Cancer Focusing on RAS Mutation. Cancers 15 (5) (2023)
Akira Ooki, Hiroki Osumi, Keisho Chin, Masayuki Watanabe, Kensei Yamaguchi
Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma. Therapeutic advances in medical oncology 15 (2023)
Shohei Udagawa, Akira Ooki, Eiji Shinozaki, Koshiro Fukuda, Kensei Yamaguchi, Hiroki Osumi
Circulating Tumor DNA: The Dawn of a New Era in the Optimization of Chemotherapeutic Strategies for Metastatic Colo-Rectal Cancer Focusing on RAS Mutation. Cancers 15 (5) (2023)
Koshiro Fukuda, Hiroki Osumi, Koichiro Yoshino, Izuma Nakayama, Shota Fukuoka, Mariko Ogura, Takeru Wakatsuki, Akira Ooki, Daisuke Takahari, Keisho Chin, Kensei Yamaguchi, Eiji Shinozaki
Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors. BMC cancer 23 (1) (2023)
Akira Ooki, Hiroki Osumi, Keisho Chin, Masayuki Watanabe, Kensei Yamaguchi
Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma. Therapeutic advances in medical oncology 15 (2023)
Hiroki Osumi, Naoki Ishizuka, Atsuo Takashima, Yosuke Kumekawa, Daisuke Nakano, Manabu Shiozawa, Tadamichi Denda, Ryoichi Sawada, Kota Ouchi, Takeru Wakatsuki, Boku Narikazu, Ken Kato, Kensei Yamaguchi, Eiji Shinozaki
Multicentre single-arm phase II trial evaluating the safety and effiCacy of Panitumumab and iRinOtecan in NeoRAS Wild-type mEtaStatic colorectal cancer patientS (C-PROWESS trial): study protocol. BMJ open 12 (9) (2022)
Hiroki Osumi, Naoki Ishizuka, Atsuo Takashima, Yosuke Kumekawa, Daisuke Nakano, Manabu Shiozawa, Tadamichi Denda, Ryoichi Sawada, Kota Ouchi, Takeru Wakatsuki, Boku Narikazu, Ken Kato, Kensei Yamaguchi, Eiji Shinozaki
Multicentre single-arm phase II trial evaluating the safety and effiCacy of Panitumumab and iRinOtecan in NeoRAS Wild-type mEtaStatic colorectal cancer patientS (C-PROWESS trial): study protocol. BMJ open 12 (9) (2022)
Hiroki Osumi, Naoki Ishizuka, Atsuo Takashima, Yosuke Kumekawa, Daisuke Nakano, Manabu Shiozawa, Tadamichi Denda, Ryoichi Sawada, Kota Ouchi, Takeru Wakatsuki, Boku Narikazu, Ken Kato, Kensei Yamaguchi, Eiji Shinozaki
Multicentre single-arm phase II trial evaluating the safety and effiCacy of Panitumumab and iRinOtecan in NeoRAS Wild-type mEtaStatic colorectal cancer patientS (C-PROWESS trial): study protocol. BMJ open 12 (9) (2022)
Hiroki Osumi, Naoki Ishizuka, Atsuo Takashima, Yosuke Kumekawa, Daisuke Nakano, Manabu Shiozawa, Tadamichi Denda, Ryoichi Sawada, Kota Ouchi, Takeru Wakatsuki, Boku Narikazu, Ken Kato, Kensei Yamaguchi, Eiji Shinozaki
Multicentre single-arm phase II trial evaluating the safety and effiCacy of Panitumumab and iRinOtecan in NeoRAS Wild-type mEtaStatic colorectal cancer patientS (C-PROWESS trial): study protocol. BMJ open 12 (9) (2022)
Hiroki Osumi, Eiji Shinozaki, Akira Ooki, Keitaro Shimozaki, Daisaku Kamiimabeppu, Izuma Nakayama, Takeru Wakatsuki, Mariko Ogura, Daisuke Takahari, Keisho Chin, Kensei Yamaguchi
Correlation between circulating tumor DNA and carcinoembryonic antigen levels in patients with metastatic colorectal cancer. Cancer medicine (2021)
Hiroki Osumi, Hiroshi Kawachi, Toshiyuki Yoshio, Junko Fujisaki
Clinical impact of Epstein-Barr virus status on the incidence of lymph node metastasis in early gastric cancer. Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 32 (3) (2020)
Hiroki Osumi, Eiji Shinozaki, Kensei Yamaguchi
Circulating Tumor DNA as a Novel Biomarker Optimizing Chemotherapy for Colorectal Cancer. Cancers 12 (6) (2020)
Hiroki Osumi, Eiji Shinozaki, Akira Ooki, Takeru Wakatsuki, Daisaku Kamiimabeppu, Taro Sato, Izuma Nakayama, Mariko Ogura, Daisuke Takahari, Keisho Chin, Kensei Yamaguchi
Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second-line chemotherapy. Cancer medicine 10 (2) (2020)
Hiroki Osumi, Eiji Shinozaki, Kensei Yamaguchi, Hitoshi Zembutsu
Clinical utility of circulating tumor DNA for colorectal cancer. Cancer science 110 (4) (2019)
Hiroki Osumi, Eiji Shinozaki, Takeru Wakatsuki, Mitsukuni Suenaga, Takashi Ichimura, Mariko Ogura, Daisuke Takahari, Akira Ooki, Takeshi Suzuki, Yumiko Ota, Izuma Nakayama, Keisho Chin, Yoshio Miki, Kensei Yamaguchi
Non-V600E BRAF mutations and EGFR signaling pathway in colorectal cancer. International journal of cancer 145 (9) (2019)
Hiroki Osumi, Eiji Shinozaki, Tetsuo Mashima, Takeru Wakatsuki, Mitsukuni Suenaga, Takashi Ichimura, Mariko Ogura, Yumiko Ota, Izuma Nakayama, Daisuke Takahari, Keisho Chin, Yoshio Miki, Kensei Yamaguchi
Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer. Cancer science 109 (8) (2018)
Hiroki Osumi, Eiji Shinozaki, Yoshinori Takeda, Takeru Wakatsuki, Takashi Ichimura, Akio Saiura, Kensei Yamaguchi, Shunji Takahashi, Tetsuo Noda, Hitoshi Zembutsu
Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer. Cancer medicine 8 (1) (2018)
Hiroki Osumi, Hiroki Osumi, Takanori Suganuma, Yusuke Horiuchi, Masami Omae, Toshiyuki Yoshio, Akiyoshi Ishiyama, Tomohiro Tsuchida, Kazumasa Miki
A significant increase in the pepsinogen I/II ratio is a reliable biomarker for successful Helicobacter pylori eradication. PloS one 12 (8) (2017)